QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Inventiva Stock Price, News & Analysis (NASDAQ:IVA)

$4.46
+0.14 (+3.24%)
(As of 12/4/2023 ET)
Compare
Today's Range
$4.33
$4.49
50-Day Range
$3.62
$4.46
52-Week Range
$2.22
$6.82
Volume
9,066 shs
Average Volume
51,238 shs
Market Capitalization
$230.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.40

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
267.7% Upside
$16.40 Price Target
Short Interest
Healthy
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.21) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

365th out of 952 stocks

Pharmaceutical Preparations Industry

162nd out of 434 stocks


IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

Brokerages Set Inventiva S.A. (NASDAQ:IVA) PT at $16.40
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Analysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)
Inventiva reports 9M results
Inventiva Share Price (IVA.PA)
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…
Inventiva ADRs Rise 9% Following Licensing Deal
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
117
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$16.40
High Stock Price Target
$35.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+267.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.83 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,192,000
Market Cap
$230.81 million
Optionable
Not Optionable
Beta
0.92

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 57)
    Co-Founder, CEO & Chairman
    Comp: $550.18k
  • Dr. Pierre Broqua Ph.D. (Age 61)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $412.67k
  • Mr. Jean Volatier (Age 58)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 49)
    General Counsel
  • Ms. Nathalie Harroy (Age 56)
    Head of Human Resources
  • Dr. Irena Konstantinova
    Head of Biology & Pharmacology
  • Dr. Michael Cooreman (Age 65)
    Chief Medical Officer
  • Mr. Jean-Paul Dutertre M.D.
    Head of Pharmacovigilance














IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

7 brokers have issued 1-year price targets for Inventiva's stock. Their IVA share price targets range from $11.00 to $35.00. On average, they expect the company's stock price to reach $16.40 in the next year. This suggests a possible upside of 267.7% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2023?

Inventiva's stock was trading at $4.46 at the start of the year. Since then, IVA stock has increased by 0.0% and is now trading at $4.46.
View the best growth stocks for 2023 here
.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Who are Inventiva's major shareholders?

Inventiva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.05%).

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -